About BlueHealer
BlueHealer designs an implantable device for bone transport, a technique used to restore blood flow and save limbs in patients with advanced vascular disease. It targets people with late-stage peripheral vascular disease or diabetes-related complications in the lower leg and foot, who risk amputation. BlueHealer's case is that today's external bone-transport frames carry a risk of infection, cause discomfort, and are used mainly at a small number of specialized centers. BlueHealer aims to build a device that surgeons already trained in bone transport can use more broadly, and its specific design remains undisclosed.
Jay Tailor is BlueHealer's chief executive officer and co-founder, and Dr. Mitchell Lipke is its CCDO and co-founder. Santiago Renteria is also an executive officer and director of the company. BlueHealer is based in Baltimore, Maryland, and remains in preclinical development; its device has not been cleared, approved, or registered for use on patients. BlueHealer has been covered by Technical.ly and Foot and Ankle News, and its project appears in Johns Hopkins University's Biomedical Engineering project gallery.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Oct 9, 2026 | Nov 4, 2026 | $1fully sold | 1 | $1 | EquityRule 506(b) | Form D ↗ |
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Why Investors Backed BlueHealer
BlueHealer is a Baltimore medical device company building an implantable device for tibial transverse bone transport, a technique aimed at saving limbs threatened by advanced vascular disease. Jay Tailor and Dr. Mitchell Lipke co-founded the company, and Santiago Renteria is also an executive officer and director. BlueHealer's case is that an implantable alternative could replace today's external bone-transport frames, which carry infection risk and see limited use. The company's device remains in preclinical development and is not yet cleared for use on patients.
The problem it targets
BlueHealer's case is that current external bone-transport frames carry a risk of infection, are poorly tolerated by patients, and are used mainly at a handful of specialized centers. The company targets patients with advanced peripheral vascular disease or diabetes-related complications in the lower leg and foot, who face the threat of amputation when these conditions go untreated.
What the product does
BlueHealer is building an implantable device that brings the bone-transport approach used in external frames inside the body. BlueHealer's case is that this design will let surgeons already trained in bone transport use it more easily, reaching more patients than today's external systems allow. The company has not disclosed how the device works, saying only that design details stay confidential while it remains in stealth.
Progress so far
Technical.ly reported on BlueHealer's work, describing its device as an internal approach to a limb-saving surgical trend. BlueHealer's project also appears in Johns Hopkins University's Biomedical Engineering project gallery. According to the Washington Informer, BlueHealer placed third at the 2026 D.C. Startup & Tech Week competition.
Who backs it
BlueHealer won a Commercialization Innovation grant from TEDCO and MBIA in 2026, one of nine Maryland startups to receive one that year. The company works out of the Johns Hopkins school for biomedical engineering and is a member of Harbor Designs. BlueHealer also took third place at the 2026 D.C. Startup & Tech Week competition.
How the market is moving
BlueHealer's case is that tibial transverse bone transport is winning more attention among orthopedic and vascular specialists as an option for patients with advanced vascular disease or diabetes-related limb complications. Foot and Ankle News posed the question, "Is Transverse Tibial Transport the Next Gold Rush?", pointing to rising interest in the approach.
We wrote this summary from public statements by BlueHealer and its investors. It is not investment advice.
BlueHealer in the News
Leadership Team
Executive officers and directors listed on BlueHealer's Form D filed Nov 4, 2026.
